Studies have found that 80% of patients are more likely to participate in a clinical trial if virtual options are available. The growth of connected devices and data management technologies is certainly setting the stage for a more decentralized future for clinical trials. Decentralizing the process also yields a more diverse, patient-centric trial design where access challenges are not a factor. Is the current biopharma industry infrastructure ready for such a vast overhaul of known clinical trial methods? Discuss both sides of the DCT coin.
